Brief: GeNeuro FY Operating Loss Narrows To 7.5 Million Euros

Geneuro SA

06/04/2021 06:30

April 6 (Reuters) - GeNeuro SA  GNRO.PA : 
    * COMPANY’S OPERATIONS FUNDED UNTIL Q2-2022
    * FY NET LOSS FOR THE PERIOD EUR 9.0 MILLION VERSUS LOSS EUR
9.5
MILLION YEAR AGO
    * FY OPERATING LOSS EUR 7.5 MILLION VERSUS LOSS EUR 9.0
MILLION
YEAR AGO
    * PRELIMINARY RESULTS ON THE ROLE OF THE HERV-W ENV PROTEIN
IN
SEVERE COVID-19 SYNDROMES MAY LEAD IN THE SHORT TERM TO NEW
INDICATIONS FOR TEMELIMAB
    * CONTINUES THE PRE-CLINICAL PROGRAM IN AMYOTROPHIC LATERAL
SCLEROSIS (ALS, IN PARTNERSHIP WITH THE US NATIONAL INSTITUTES
OF HEALTH), AND SEEK A PARTNER TO BRING THIS PROJECT TO AN IND
BY 2022
    * CLINICAL TRIAL OF TEMELIMAB IN MULTIPLE SCLEROSIS (MS)
WITH
KAROLINSKA INSTITUTET / ACADEMIC SPECIALIST CENTER OF STOCKHOLM,
ON TRACK TO DELIVER RESULTS IN Q1 2022

Source text for Eikon:  ID:nBw3NNNHFa 
Further company coverage:  GNRO.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))